keyword
MENU ▼
Read by QxMD icon Read
search

Breast cancer her2+ recurrence

keyword
https://www.readbyqxmd.com/read/28811185/the-effect-of-receptor-status-on-mastectomy-and-contralateral-prophylactic-mastectomy-rates-in-early-stage-invasive-breast-carcinoma
#1
Sunil W Dutta, Daniel M Trifiletti, Surbhi Grover, Kara D Romano, Einsley-Marie Janowski, Shayna L Showalter
BACKGROUND: There is an established relationship between hormone receptor (HR; estrogen and/or progesterone receptors) status, HER2 status, and locoregional recurrence. The purpose of this study was to analyze how HR and HER2 receptor status have influenced the surgical management trends among patients with early stage breast cancer. PATIENTS AND METHODS: The National Cancer Database was queried for patients with cT1 to cT3, cN0, and cM0 breast carcinoma from 2004 to 2012...
June 29, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28810292/-clinicopathologic-features-of-mammary-microglandular-adenosis-with-carcinoma-a-study-of-5-cases
#2
W Chen, C Wang, Z H Zhang, W M Zhang, Y Xu, G X Song
Objective: To study the clinicopathologic, immunohistochemical features, differential diagnoses and prognosis of mammary microglandular adenosis with carcinoma (MGACA) with micropapillary pattern. Methods: Five cases of MGACA were collected from 2010 to 2016 and reviewed for their clinical, histologic features and outcome.EnVision method were done for S-100 protein, cytokeratin (CK), p63, Calponin, smooth muscle myosin heavy chain (SMMHC), PR, ER and HER2. Results: Histologically, microglandular adenosis(MGA), atypical MGA (AMGA) and invasive carcinoma were seen in all five cases of MGACA...
August 8, 2017: Zhonghua Bing Li Xue za Zhi Chinese Journal of Pathology
https://www.readbyqxmd.com/read/28794284/genomic-profiling-of-er-breast-cancers-after-short-term-estrogen-suppression-reveals-alterations-associated-with-endocrine-resistance
#3
Jennifer M Giltnane, Katherine E Hutchinson, Thomas P Stricker, Luigi Formisano, Christian D Young, Monica V Estrada, Mellissa J Nixon, Liping Du, Violeta Sanchez, Paula Gonzalez Ericsson, Maria G Kuba, Melinda E Sanders, Xinmeng J Mu, Eliezer M Van Allen, Nikhil Wagle, Ingrid A Mayer, Vandana Abramson, Henry Gόmez, Monica Rizzo, Weiyi Toy, Sarat Chandarlapaty, Erica L Mayer, Jason Christiansen, Danielle Murphy, Kerry Fitzgerald, Kai Wang, Jeffrey S Ross, Vincent A Miller, Phillip J Stephens, Roman Yelensky, Levi Garraway, Yu Shyr, Ingrid Meszoely, Justin M Balko, Carlos L Arteaga
Inhibition of proliferation in estrogen receptor-positive (ER(+)) breast cancers after short-term antiestrogen therapy correlates with long-term patient outcome. We profiled 155 ER(+)/human epidermal growth factor receptor 2-negative (HER2(-)) early breast cancers from 143 patients treated with the aromatase inhibitor letrozole for 10 to 21 days before surgery. Twenty-one percent of tumors remained highly proliferative, suggesting that these tumors harbor alterations associated with intrinsic endocrine therapy resistance...
August 9, 2017: Science Translational Medicine
https://www.readbyqxmd.com/read/28791482/assessment-of-ki67-expression-for-breast-cancer-subtype-classification-and-prognosis-in-the-nurses-health-study
#4
Megan A Healey, Kelly A Hirko, Andrew H Beck, Laura C Collins, Stuart J Schnitt, A Heather Eliassen, Michelle D Holmes, Rulla M Tamimi, Aditi Hazra
PURPOSE: Ki67 is a proliferation marker commonly assessed by immunohistochemistry in breast cancer, and it has been proposed as a clinical marker for subtype classification, prognosis, and prediction of therapeutic response. However, the clinical utility of Ki67 is limited by the lack of consensus on the optimal cut point for each application. METHODS: We assessed Ki67 by immunohistochemistry using Definiens digital image analysis (DIA) in 2653 cases of incident invasive breast cancer diagnosed in the Nurses' Health Study from 1976 to 2006...
August 8, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28790119/complementary-value-of-contralateral-parenchymal-enhancement-on-dce-mri-to-prognostic-models-and-molecular-assays-in-high-risk-er-her2-breast-cancer
#5
Bas H M van der Velden, Sjoerd G Elias, Tycho Bismeijer, Claudette E Loo, Max A Viergever, Lodewyk F A Wessels, Kenneth G A Gilhuijs
Purpose: To determine whether markers of healthy breast stroma are able to select a subgroup of patients at low risk of death or metastasis from patients considered at high risk according to routine markers of the tumor. <p>Experimental Design: Patients with ER-positive/HER2-negative breast cancer were consecutively included for retrospective analysis. The contralateral parenchyma was segmented automatically on dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), whereupon the average of the top-10% late enhancement was calculated...
August 8, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28770452/pertuzumab-for-the-neoadjuvant-treatment-of-early-stage-her2-positive-breast-cancer-an-evidence-review-group-perspective-of-a-nice-single-technology-appraisal
#6
REVIEW
Hazel Squires, Abdullah Pandor, Praveen Thokala, John W Stevens, Eva Kaltenthaler, Mark Clowes, Robert Coleman, Lynda Wyld
As part of its single technology appraisal process, the National Institute for Health and Care Excellence invited the manufacturer of pertuzumab (Perjeta(®); Roche Products Limited) to submit evidence of its clinical and cost- effectiveness for the neoadjuvant treatment of women with high-risk, early-stage, HER2-positive breast cancer when used in combination with trastuzumab and chemotherapy. High-risk women included those with locally advanced (including inflammatory) breast cancer and women with high-risk early-stage breast cancer (classified as T2/3 or N1)...
August 2, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28766220/improved-locoregional-control-in-a-contemporary-cohort-of-nonmetastatic-inflammatory-breast-cancer-patients-undergoing-surgery
#7
Kelly J Rosso, Audree B Tadros, Anna Weiss, Carla L Warneke, Sarah DeSnyder, Henry Kuerer, Naoto T Ueno, Shane R Stecklein, Wendy A Woodward, Anthony Lucci
BACKGROUND: Inflammatory breast cancer (IBC) is an aggressive form of breast cancer characterized by rapid progression and early metastatic dissemination. The purpose of this study was to assess contemporary rates of local regional recurrence (LRR) in the era of trimodality therapy for nonmetastatic IBC and identify risk factors leading to local failure. METHODS: A total of 114 patients with nonmetastatic IBC receiving trimodality therapy (neoadjuvant chemotherapy, surgery, and radiation therapy) were identified from a prospectively collected database from 2007 to 2015 and outcomes analyzed...
August 1, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28759039/elevated-tumor-ldlr-expression-accelerates-ldl-cholesterol-mediated-breast-cancer-growth-in-mouse-models-of-hyperlipidemia
#8
E J Gallagher, Z Zelenko, B A Neel, I M Antoniou, L Rajan, N Kase, D LeRoith
Obesity is associated with an increase in cancer-specific mortality in women with breast cancer. Elevated cholesterol, particularly low-density lipoprotein cholesterol (LDL-C), is frequently seen in obese women. Here, we aimed to determine the importance of elevated circulating LDL, and LDL receptor (LDLR) expression in tumor cells, on the growth of breast cancer using mouse models of hyperlipidemia. We describe two novel immunodeficient mouse models of hyperlipidemia (Rag1(-/)(-)/LDLR(-/)(-) and Rag1(-/)(-)/ApoE (apolipoprotein E)(-/)(-) mice) in addition to established immunocompetent LDLR(-/)(-) and ApoE(-/)(-) mice...
July 31, 2017: Oncogene
https://www.readbyqxmd.com/read/28755141/locoregional-recurrence-following-breast-cancer-surgery-in-the-trastuzumab-era-a-systematic-review-by-subtype
#9
Andrew McGuire, Aoife J Lowery, Malcolm R Kell, Michael J Kerin, Karl J Sweeney
INTRODUCTION: Increasing evidence suggests that molecular subtype influences locoregional recurrence (LRR) of breast cancer. Previous systematic reviews that evaluated the quantitative influence of subtype on LRR predated the use of Trastuzumab. This study assessed the impact of subtype on LRR in a contemporary treatment era. METHODS: A comprehensive search for all published studies assessing LRR according to breast cancer subtype was performed. Only studies with patients treated with Trastuzumab were included...
July 28, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28754844/mitochondrial-markers-predict-recurrence-metastasis-and-tamoxifen-resistance-in-breast-cancer-patients-early-detection-of-treatment-failure-with-companion-diagnostics
#10
Federica Sotgia, Marco Fiorillo, Michael P Lisanti
Here, we used a data-mining and informatics approach to discover new biomarkers of resistance to hormonal therapy in breast cancer. More specifically, we investigated whether nuclear-encoded genes associated with mitochondrial biogenesis can be used to predict tumor recurrence, distant metastasis and treatment failure in high-risk breast cancer patients. Overall, this strategy allowed us to directly provide in silico validation of the prognostic value of these mitochondrial components in large and clinically relevant patient populations, with >15 years of follow-up data...
July 27, 2017: Oncotarget
https://www.readbyqxmd.com/read/28739750/impact-of-a-21-gene-recurrence-score-test-on-the-choice-of-adjuvant-chemotherapy-for-hormone-receptor-positive-early-stage-breast-cancer-a-prospective-study
#11
Yinduo Zeng, Qian Li, Tao Qin, Shunrong Li, Liang Jin, Jiannan Wu, Kai Chen, Heran Deng, Nanyan Rao, Qiang Liu, Fengxi Su, Weijuan Jia, Herui Yao
BACKGROUND: Studies have recommended a 21-gene recurrence score (RS) to optimize adjuvant treatment for patients with early-stage breast cancer (EBC) with hormone receptor-positive (HR(+)) and human epidermal growth factor receptor-2 negative (HER2(-)) tumors. This study aimed to prospectively evaluate the impact of this RS in Chinese patients with breast cancer. PATIENTS AND METHODS: We prospectively collected 227 patients with EBC with estrogen receptor-positive (ER(+)) and HER2(-) tumors...
August 2017: Anticancer Research
https://www.readbyqxmd.com/read/28721065/optimizing-the-treatment-of-bevacizumab-as-first-line-therapy-for-human-epidermal-growth-factor-receptor-2-her2-negative-advanced-breast-cancer-an-updated-meta-analysis-of-published-randomized-trials
#12
Cunfu Li, Aizhai Xiang, Xianzhi Chen, Kai Yin, Jinsong Lu, Wenjin Yin
BACKGROUND: Manifold data have demonstrated that the addition of bevacizumab to chemotherapy improved progression-free survival (PFS), while few trials have revealed its significant overall survival (OS) benefit. Furthermore, it still remains suspended how to maximize the benefits of bevacizumab as first-line therapy for human epidermal growth factor receptor 2 (HER2)-negative breast cancer. We sought to conduct a meta-analysis to assess the benefits of bevacizumab with chemotherapy and to identify the ideal chemotherapy partner of bevacizumab in the first-line setting for HER2-negative advanced breast cancer patients...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28707744/the-impact-of-molecular-subtype-on-breast-cancer-recurrence-in-young-women-treated-with-contemporary-adjuvant-therapy
#13
Hanan Alabdulkareem, Tiffany Pinchinat, Sarah Khan, Alyssa Landers, Paul Christos, Rache Simmons, Tracy-Ann Moo
Breast cancer is the leading cause of cancer death in women younger than 40 years. Triple-negative breast cancer (TNBC) and human epidermal growth factor receptor-2 (HER2) positive subtypes have a particularly poor prognosis in this age group. The purpose of this study was to compare rates of recurrence among breast cancer subtypes in young patients treated with modern adjuvant systemic therapy. A retrospective review of breast cancer patients managed at a major academic breast center between May 2000 and November 2014 was performed...
July 14, 2017: Breast Journal
https://www.readbyqxmd.com/read/28702894/21-gene-recurrence-score-and-locoregional-recurrence-in-lymph-node-negative-estrogen-receptor-positive-breast-cancer
#14
Gulisa Turashvili, Joanne F Chou, Edi Brogi, Monica Morrow, Maura Dickler, Larry Norton, Clifford Hudis, Hannah Y Wen
BACKGROUND/PURPOSE: The 21-gene recurrence score (RS) assay evaluates the likelihood of distant recurrence and benefit of chemotherapy in lymph node-negative, estrogen receptor (ER)-positive, HER2-negative breast cancer patients. The RS categories are associated with the risk of locoregional recurrence (LRR) in some, but not all studies. METHODS: We reviewed the institutional database to identify consecutive female patients with node-negative, ER+/HER2- breast carcinoma tested for the 21-gene RS assay and treated at our center from 2008 to 2013...
July 12, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28690659/chronic-myeloid-leukemia-with-a-complex-variant-ph-translocation-that-develops-in-breast-carcinoma-postchemotherapy-a-rare-but-treatable-entity
#15
Gargi Tikku, Monica Jain, Pragya Shukla
We report a case of chronic myeloid leukemia (CML) that developed after postoperative chemotherapy with cyclophosphamide, doxorubicin and 5-fluorouracil (CAF) for breast cancer. A 55-year-old woman was diagnosed with invasive ductal carcinoma which was treated with a modified radical mastectomy followed by six cycles of CAF chemotherapy. Nine years later, she developed CML and locoregional recurrence. Her breast recurrence showed strong estrogen receptor, weak progesterone receptor and strong human epidermal growth factor 2 (score 3+) expression...
June 2017: Journal of Breast Cancer
https://www.readbyqxmd.com/read/28690656/imaging-surveillance-for-survivors-of-breast-cancer-correlation-between-cancer-characteristics-and-method-of-detection
#16
A Jung Chu, Jung Min Chang, Nariya Cho, Woo Kyung Moon
PURPOSE: The aim of our study was to investigate the characteristics of primary and recurrent breast cancers and the correlation between cancer subtypes and detection modes. METHODS: Between 2003 and 2013, 147 cases of recurrent breast cancer in 137 women (mean age, 45.30±10.78 years) were identified via an annual clinical examination using radiological studies among 6,169 patients with a breast cancer history (mean follow-up period, 13.26±1.78 years). Clinical, radiological, and pathological findings including immunohistochemistry findings of primary and recurrent cancers were reviewed...
June 2017: Journal of Breast Cancer
https://www.readbyqxmd.com/read/28689364/oncologists-influence-on-receipt-of-adjuvant-chemotherapy-does-it-matter-whom-you-see-for-treatment-of-curable-breast-cancer
#17
Steven J Katz, Sarah T Hawley, Irina Bondarenko, Reshma Jagsi, Kevin C Ward, Timothy P Hofer, Allison W Kurian
PURPOSE: We know little about whether it matters which oncologist a breast cancer patient sees with regard to receipt of chemotherapy. We examined oncologists' influence on use of recurrence score (RS) testing and chemotherapy in the community. METHODS: We identified 7810 women with stages 0-II breast cancer treated in 2013-15 through the SEER registries of Georgia and Los Angeles County. Surveys were sent 2 months post-surgery, (70% response rate, n = 5080)...
July 8, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28689362/predictive-factors-on-outcomes-in-metaplastic-breast-cancer
#18
REVIEW
C Marc Leyrer, Camille A Berriochoa, Shree Agrawal, Alana Donaldson, Benjamin C Calhoun, Chirag Shah, Robyn Stewart, Halle C F Moore, Rahul D Tendulkar
PURPOSE: Metaplastic breast cancer (MBC) is a rare, aggressive variant of breast cancer, with limited data available regarding treatment and outcomes. This study aims to review patients with MBC treated at our tertiary care institution with an emphasis on the role of treatment modality and histologic classification. METHODS: With IRB-approval, we queried our pathology database for patients with MBC diagnosis. All cases were re-evaluated by dedicated breast pathologists and confirmed as MBC breast cancer...
July 8, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28674022/fsip1-binds-her2-directly-to-regulate-breast-cancer-growth-and-invasiveness
#19
Tong Liu, Hao Zhang, Li Sun, Danyu Zhao, Peng Liu, Meisi Yan, Neeha Zaidi, Sudeh Izadmehr, Animesh Gupta, Wahid Abu-Amer, Minna Luo, Jie Yang, Xunyan Ou, Yining Wang, Xuefeng Bai, Yan Wang, Maria I New, Mone Zaidi, Tony Yuen, Caigang Liu
Fibrous sheath interacting protein 1 (FSIP1), a spermatogenesis-related testicular antigen, is expressed in abundance in breast cancers, particularly in those overexpressing human epidermal growth factor receptor 2 (HER2); however, little is known about its role in regulating the growth and metastasis of breast cancer cells. We and others have shown previously that FSIP1 expression in breast cancer correlates positively with HER2-positivity, recurrence, and metastases and negatively with survival. Here, using coimmunoprecipitation and microscale thermophoresis, we find that FSIP1 binds to the intracellular domain of HER2 directly...
July 18, 2017: Proceedings of the National Academy of Sciences of the United States of America
https://www.readbyqxmd.com/read/28673861/cpsf6-is-a-clinically-relevant-breast-cancer-vulnerability-target-role-of-cpsf6-in-breast-cancer
#20
Najat Binothman, Ibrahim Y Hachim, Jean-Jacques Lebrun, Suhad Ali
Breast cancer represents a major health challenge. The majority of breast cancer deaths are due to cancer progression/recurrence for which no efficient therapies exist. Aggressive breast cancers are characterized by loss of cellular differentiation. Defining molecular mechanisms/targets contributing to cancer aggressiveness is needed to guide the design of new screening and targeted treatments. Here, we describe a novel tumor promoting function for the Cleavage and Polyadenylation Factor-6 (CPSF6). Importantly, aggressive breast cancer cells of luminal B, HER2-overexpressing and triple negative subtypes show dependency on CPSF6 for viability and tumorigenic capacity...
July 2017: EBioMedicine
keyword
keyword
115348
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"